JPMorgan Chase & Co. Issues Pessimistic Forecast for Charles River Laboratories International (NYSE:CRL) Stock Price

Charles River Laboratories International (NYSE:CRL) had its target price reduced by JPMorgan Chase & Co. from $215.00 to $175.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a neutral rating on the medical research company’s stock.

CRL has been the topic of several other reports. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. UBS Group reaffirmed a “neutral” rating and set a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Evercore ISI upped their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. Finally, CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective for the company. in a report on Monday, November 18th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $202.08.

Charles River Laboratories International Price Performance

CRL stock opened at $161.72 on Monday. The company’s fifty day simple moving average is $183.36 and its 200 day simple moving average is $194.86. Charles River Laboratories International has a 12-month low of $159.65 and a 12-month high of $275.00. The firm has a market cap of $8.27 billion, a price-to-earnings ratio of 20.24, a PEG ratio of 6.25 and a beta of 1.38. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same period last year, the company posted $2.72 earnings per share. The business’s quarterly revenue was down 1.6% on a year-over-year basis. On average, analysts expect that Charles River Laboratories International will post 10.17 earnings per share for the current year.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CRL. Olympiad Research LP purchased a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $267,000. VisionPoint Advisory Group LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter worth approximately $1,751,000. Handelsbanken Fonder AB raised its position in shares of Charles River Laboratories International by 1.6% in the fourth quarter. Handelsbanken Fonder AB now owns 12,437 shares of the medical research company’s stock valued at $2,296,000 after buying an additional 200 shares during the last quarter. Bryn Mawr Capital Management LLC grew its position in shares of Charles River Laboratories International by 1,871.2% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 35,659 shares of the medical research company’s stock valued at $6,583,000 after purchasing an additional 33,850 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its stake in shares of Charles River Laboratories International by 170.2% in the 4th quarter. Venturi Wealth Management LLC now owns 4,367 shares of the medical research company’s stock worth $806,000 after acquiring an additional 2,751 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).